Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor

Cancer

Volumn 117, Issue 21, 2011, Pages 4939-4947

  Park, Min S ^a   Patel, Shreyaskumar R ^a   Ludwig, Joseph A ^a   Trent, Jonathan C ^a   Conrad, Charles A ^a   Lazar, Alexander J ^a   Wang, Wei Lien ^a   Boonsirikamchai, Piyaporn ^a   Choi, Haesun ^a   Wang, Xuemei ^a   Benjamin, Robert S ^a   Araujo, Dejka M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

anti angiogenesis inhibitors; chemotherapy; hemangiopericytoma; soft tissue sarcoma; solitary fibrous tumors

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; FLUCONAZOLE; TEMOZOLOMIDE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; CRYPTOCOCCOSIS; DEATH; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEMANGIOPERICYTOMA; HISTOPATHOLOGY; HUMAN; HYPOTENSION; KIDNEY FAILURE; LUNG INFILTRATE; MALE; MENTAL HEALTH; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SOLITARY FIBROUS TUMOR; STAPHYLOCOCCUS INFECTION; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; FEMALE; HEMANGIOPERICYTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; SOLITARY FIBROUS TUMORS; TREATMENT OUTCOME;

EID: 79961219491     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26098     Document Type: Article

References (32)

1. Fletcher CD,. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology. 2006; 48: 3-12.
2. Gengler C, Guillou L,. Solitary fibrous tumour and haemangiopericytoma: evolution of a concept. Histopathology. 2006; 48: 63-74.
3. Enzinger FM, Smith BH,. Hemangiopericytoma. An analysis of 106 cases. Hum Pathol. 1976; 7: 61-82.
4. Mena H, Ribas JL, Pezeshkpour GH, Cowan DN, Parisi JE,. Hemangiopericytoma of the central nervous system: a review of 94 cases. Hum Pathol. 1991; 22: 84-91.
5. Park MS, Araujo DM,. New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors. Curr Opin Oncol. 2009; 21: 327-331.
6. Spitz FR, Bouvet M, Pisters PW, Pollock RE, Feig BW,. Hemangiopericytoma: a 20-year single-institution experience. Ann Surg Oncol. 1998; 5: 350-355. (Pubitemid 28272439)
7. Espat NJ, Lewis JJ, Leung D, et al. Conventional hemangiopericytoma: modern analysis of outcome. Cancer. 2002; 95: 1746-1751.
8. Magdeleinat P, Alifano M, Petino A, et al. Solitary fibrous tumors of the pleura: clinical characteristics, surgical treatment and outcome. Eur J Cardiothorac Surg. 2002; 21: 1087-1093.
9. Guthrie BL, Ebersold MJ, Scheithauer BW, Shaw EG,. Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery. 1989; 25: 514-522. (Pubitemid 19236255)
10. Soyuer S, Chang EL, Selek U, McCutcheon IE, Maor MH,. Intracranial meningeal hemangiopericytoma: the role of radiotherapy: report of 29 cases and review of the literature. Cancer. 2004; 100: 1491-1497. (Pubitemid 38366853)
11. Beadle GF, Hillcoat BL,. Treatment of advanced malignant hemangiopericytoma with combination adriamycin and DTIC: a report of four cases. J Surg Oncol. 1983; 22: 167-170. (Pubitemid 13120964)
12. Galanis E, Buckner JC, Scheithauer BW, Kimmel DW, Schomberg PJ, Piepgras DG,. Management of recurrent meningeal hemangiopericytoma. Cancer. 1998; 82: 1915-1920. (Pubitemid 28208648)
13. Chamberlain MC, Glantz MJ,. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma. Neurosurgery. 2008; 63: 720-726; author reply 26-27.
14. Park MS, Lazar AJ, Trent JC, et al. Combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma/solitary fibrous tumor: an updated analysis [Abstract 35064]. Presented at the 14th Connective Tissue Oncologic Society Annual Meeting; November 13-15, 2008; London, United Kingdom.
15. Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I,. Systemic therapy in solitary fibrous tumour [Abstract 39407]. Presented at the 15th Connective Tissue Oncologic Society Annual Meeting; November 5-7, 2009; Miami Beach, Florida.
16. Gottlieb JA, Benjamin RS, Baker LH, et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep. 1976; 60: 199-203.
17. Trent JC, Beach J, Burgess MA, et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer. 2003; 98: 2693-2699. (Pubitemid 37509535)
18. Ellis LM, Hicklin DJ,. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8: 579-591.
19. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342. (Pubitemid 38702844)
20. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550. (Pubitemid 44917502)
21. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357: 2666-2676.
22. ClinicalTrials.gov. Available at: Accessed September 1, 2010.
23. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007; 25: 1753-1759. (Pubitemid 46797957)
24. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007; 25: 1760-1764. (Pubitemid 46797958)
25. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
26. Fletcher CDM, Unni KK, Mertens F,. World Health Organization classification of tumours. Pathology and genetics. Tumours of soft tissue and bone. Lyon, France: IARC Press; 2002.
27. Kaplan E, Meier P,. Nonparametric estimator from incomplete observations. J American Statistical Association. 1958; 53: 457-481.
28. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007; 8: 595-602. (Pubitemid 46995623)
29. Casali PG, Messina A, Stacchiotti S, et al. Imatinib mesylate in chordoma. Cancer. 2004; 101: 2086-2097. (Pubitemid 39425386)
30. Ryan CW, von Mehren M, Rankin CJ, et al. Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505 [abstract]. J Clin Oncol. 2008; 26 (suppl). Abstract 10532.
31. Casali PG, Stacchiotti S, Palassini E, et al. Evaluation of the antitumor activity of sunitinib malate (SM) in solitary fibrous tumor (SFT) [abstract]. J Clin Oncol. 2009; 27 (suppl). Abstract 10571.
32. Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009; 27: 3133-3140.